Wet-suction Versus Slow-pull for EUS-FNB of Solid Lesions (WEST-FNB)

March 19, 2022 updated by: Stefano Francesco Crinò, MD, Azienda Ospedaliera Universitaria Integrata Verona

Wet-suction Versus Slow-pull Technique for Endoscopic Ultrasound-guided Fine-needle Biopsy of Solid Lesions: a Multicentric Randomized Controlled Trial

A randomized cross-over study investigating the impact of two different suction techniques on histological yield and sample quality of specimens collected by endoscopic ultrasound biopsy from solid lesions using histology needles.

Study Overview

Study Type

Interventional

Enrollment (Actual)

200

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Verona, Italy, 37134
        • Azienda Ospedaliera Integrata Verona

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Solid pancreatic lesions 3 1cm
  • Peri-GI tract lymph nodes 3 1cm
  • Peri-GI tract masses
  • Lesions of the GI wall
  • Signed informed consent

Exclusion Criteria:

  • Pancreatic cystic lesions (more than 50% of the volume)
  • Diameter of lesion ≤ 1 cm
  • Lesion not seen at EUS
  • Pregnancy
  • Coagulopathy (platelet count <50.000/mm3 and/or international normalized ratio >1.5);
  • Severe cardiorespiratory dysfunction precluding endoscopy;
  • Failure to provide informed consent

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: WET-SUCTION
The stylet will be removed and the needle will be pre-flushed with 1-2mL of saline. The lesion will then be punctured, and suction will be applied using a 10-mL pre-vacuum syringe. The sample collected will be pushed into a formalin vial with saline.
Solid lesions will be sampled under endoscopic ultrasound guidance using the two techniques (wet-suction and slow-pull)
Active Comparator: SLOW-PULL
After puncturing the lesion, the stylet will be slowly and gradually withdrawn for at least 40cm. The sample will be pushed into formalin using the stylet.
Solid lesions will be sampled under endoscopic ultrasound guidance using the two techniques (wet-suction and slow-pull)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Histologic yield
Time Frame: 6 months
The rate of samples containing a tissue "core" (yes/no) for histological evaluation, defined as an intact piece of tissue of at least 550 μ
6 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Tissue integrity
Time Frame: 6 months

Tissue integrity will be evaluated by attributing a score from zero to 3 (3 represents the better outcome), according to the following score system:

0: No cells/tissue

  1. Cytological specimen (disaggregated cells representative of the target lesion not allowing for tissue architectural assessment)
  2. Histologic microfragments (sample adequate for histological evaluation, namely an architecturally intact piece of tissue but without a "core")
  3. Histologic "core" (defined as an architecturally intact piece of tissue measuring at least 550 μ)
6 months
Blood contamination
Time Frame: 6 months

Blood contamination will be evaluated by attributing a score from zero to 3 (3 represents the better outcome), according to the following score system:

0: Only blood

  1. High blood contamination (>50% of the surface)
  2. Moderate blood contamination (25-50% of the surface)
  3. Low blood contamination (<25% of the surface)
6 months
Tumor fraction
Time Frame: 6 months
The rate of samples containing an adequate tumor fraction ≥20 percent (i.e., ≥ 20 percent tumor cells in a background of benign nucleated cells).
6 months
Diagnostic accuracy
Time Frame: 6 months
Diagnostic accuracy (defined as the ratio between the sum of true positive and true negative values divided by the number of lesions) will be calculated for each study arm
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 29, 2021

Primary Completion (Actual)

October 30, 2021

Study Completion (Anticipated)

April 30, 2022

Study Registration Dates

First Submitted

March 29, 2021

First Submitted That Met QC Criteria

April 5, 2021

First Posted (Actual)

April 8, 2021

Study Record Updates

Last Update Posted (Actual)

March 22, 2022

Last Update Submitted That Met QC Criteria

March 19, 2022

Last Verified

March 1, 2022

More Information

Terms related to this study

Other Study ID Numbers

  • 18/22.09.2020

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Endoscopic Ultrasound

Clinical Trials on Endoscopic ultrasound-guided fine-needle biopsy

Subscribe